Gland Pharma Limited
Momentum (99/100) does the heavy lifting; valuation (62/100) is the drag.
Buy zoneGland Pharma Limited earns a Strong Buy from StocksWizard, with a blended score of 79/100. At ₹2,502.9 it trades below our blended DCF and relative-multiples fair value of ₹2,631.69, about 5% upside to that estimate — we read it as fairly valued. On 37.4x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹2,550. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 8/9. The average analyst target of ₹2,189.57 implies about 13% downside across 14 analysts. It clears 11 of 13 investability checks, with durability 75, valuation 66 and momentum 99 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹2,105.35.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-1.85% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Buy79Piotroski F-score 8/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 10.5%
- Pass: Low debt (D/E < 0.5): 0.03x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 22%
- Pass: Earnings growing: 96%
- Pass: Net margin ≥ 10%: 16.0%
- Pass: Current ratio > 1.5: 4.68
- Pass: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 12.58
- Pass: Piotroski ≥ 7: 8/9
Quarterly results
Annual financials
Shareholding
- Promoter51.8%
- Institutions36.3%
- Public & other11.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (16.0%).
- Trading near its 52-week high.
- Financially solid — Altman Z 12.58.
- High Piotroski quality score (8/9).
Opportunities
- Earnings growing (96% YoY).
- Revenue growing (22% YoY).
- Trading in our value buy zone versus sector peers.
About Gland Pharma Limited
Gland Pharma Limited manufactures and sells injectable formulations globally, including in India, the United States, Europe, Canada, Australia, and New Zealand. The company develops active pharmaceutical ingredients through synthesis of complex molecules such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic compounds for various therapeutic categories.
Gland Pharma Limited — frequently asked questions
Is Gland Pharma Limited a buy, hold or sell?
StocksWizard currently rates Gland Pharma Limited (GLAND) a Strong Buy, based on a blended score of 79/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Gland Pharma Limited's fair value?
Our blended DCF and relative-valuation model estimates Gland Pharma Limited's fair value at about ₹2,631.69, versus a current price of ₹2,502.9 — roughly 5% upside. On that basis the stock looks fairly valued.
Is Gland Pharma Limited financially healthy?
Gland Pharma Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 8/9.
How has Gland Pharma Limited's share price performed?
Gland Pharma Limited is up 41% over three months, and last traded at ₹2,502.9. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.